R&D channel feed – Endpoints News

R&D channel feed

10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul

8 years ago

Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul

8 years ago

After a $200M financing, Highland Therapeutics falls silent on ADHD drug’s fate as PDUFA sails by

8 years ago

Spark Therapeutics offers a glimpse of efficacy in first two hemophilia A gene therapy patients

8 years ago

Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib

8 years ago

InVivo Therapeutics shares tank after a third patient death in lead study

8 years ago

Dynavax takes a big step toward an OK for hep B vaccine, but nagging safety issues remain

8 years ago

Merck admits cyberattack is having an impact on research, manufacturing — we're just not sure how big

8 years ago

The global rivalry for top scientific talent in biopharma R&D is about to get a lot hotter

8 years ago

CheckMate-227: Bristol-Myers Squibb has a MYSTIC-sized problem on its hands

8 years ago

J&J sews up an expanded vaccine pact with Bavarian Nordic, paying $43M for HIV, hep B projects

8 years ago

Alexion joins the R&D reorganization gala, pruning a slate of projects and revving up new deals

8 years ago

AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails and shares plunge

8 years ago

Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav

8 years ago

Tetraphase lines up a new FDA pitch for antibiotic after it comes through in latest PhIII

8 years ago

GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research

8 years ago

Neuralstem’s lead drug crumbles in PhII, adding to a litany of failures for depression drugs and blasting shares

8 years ago

Biogen lays out a plan to “streamline” ops, add $400M to fund neurosciences R&D, new deals

8 years ago

Restructuring the pipeline, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years

8 years ago

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

8 years ago

Trading places with Bristol-Myers, Merck hit with another late-stage setback on checkpoint star Keytruda

8 years ago

Troubled Teva brings out the ax as it cuts deep into its Israeli pharma group

8 years ago

Another micro-cap biotech has flunked a pivotal test for a regenerative cell therapy

8 years ago

Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug

8 years ago

First page Previous page 294 295 296297298 299 300 Next page Last page